These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29286561)

  • 1. Intracranial metastasis in fibrolamellar hepatocellular carcinoma.
    Hammond WJ; Lalazar G; Saltsman JA; Farber BA; Danzer E; Sherpa TC; Banda CD; Andolina JR; Karimi S; Brennan CW; Torbenson MS; La Quaglia MP; Simon SM
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1.
    Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM
    Cancer Res; 2024 Aug; 84(16):2626-2644. PubMed ID: 38888469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
    Reid LM; Sethupathy P
    Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
    Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
    Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
    Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
    Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
    Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
    Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
    Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
    Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
    Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
    Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
    Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in fibrolamellar hepatocellular carcinoma: a review.
    Lim II; Farber BA; LaQuaglia MP
    Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma.
    Tomasini MD; Wang Y; Karamafrooz A; Li G; Beuming T; Gao J; Taylor SS; Veglia G; Simon SM
    Sci Rep; 2018 Jan; 8(1):720. PubMed ID: 29335433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
    Karamafrooz A; Brennan J; Thomas DD; Parker LL
    J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
    Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
    Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.